BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ. 1988;297:1501-1504. [PMID: 3147046 DOI: 10.1136/bmj.297.6662.1501] [Cited by in Crossref: 216] [Cited by in F6Publishing: 195] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Ho V, Stewart M, Boyd P. Cholestatic hepatitis as a possible new side-effect of oxycodone: a case report. J Med Case Rep 2008;2:140. [PMID: 18452597 DOI: 10.1186/1752-1947-2-140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Abbas G, Jorgensen RA, Lindor KD. Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol. 2010;7:313-319. [PMID: 20458334 DOI: 10.1038/nrgastro.2010.62] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
3 Bergasa NV. Lysophosphatidic acid and atotaxin in patients with cholestasis and pruritus: Fine biology, anticipated discernment. Annals of Hepatology 2010;9:475-9. [DOI: 10.1016/s1665-2681(19)31629-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Bergasa NV. The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years. Medical Hypotheses 2018;110:86-9. [DOI: 10.1016/j.mehy.2017.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
5 Simon FR. DRUG-INDUCED CHOLESTASIS. Clinics in Liver Disease 1998;2:483-99. [DOI: 10.1016/s1089-3261(05)70023-4] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
6 Sood A, Midha V, Sood N. Pruritus can be soothing in acute viral hepatitis. Am J Gastroenterol 2001;96:2282-3. [DOI: 10.1111/j.1572-0241.2001.03994.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
7 Marzioni M, Svegliati Baroni G, Alpini G, Benedetti A. Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol 2007;46:583-6. [PMID: 17313989 DOI: 10.1016/j.jhep.2007.01.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
8 Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OFW. A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 1994;9:162-8. [DOI: 10.1111/j.1440-1746.1994.tb01237.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.1] [Reference Citation Analysis]
9 Düll MM, Kremer AE. Treatment of Pruritus Secondary to Liver Disease. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0713-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
10 Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, Nagase H. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol. 2003;477:29-35. [PMID: 14512095 DOI: 10.1016/j.ejphar.2003.08.007] [Cited by in Crossref: 99] [Cited by in F6Publishing: 76] [Article Influence: 5.5] [Reference Citation Analysis]
11 Valeria Bergasa N, Alling DW, Vergalla J, Anthony Jones E. Cholestasis in the male rat is associated with naloxone-reversible antinociception. Journal of Hepatology 1994;20:85-90. [DOI: 10.1016/s0168-8278(05)80471-4] [Cited by in Crossref: 82] [Cited by in F6Publishing: 7] [Article Influence: 2.9] [Reference Citation Analysis]
12 Trivedi HD, Lizaola B, Tapper EB, Bonder A. Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. The American Journal of Medicine 2017;130:744.e1-7. [DOI: 10.1016/j.amjmed.2017.01.037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
13 Luketic VA, Shiffman ML. BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS. Clinics in Liver Disease 1999;3:509-28. [DOI: 10.1016/s1089-3261(05)70083-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Hope AA, Morrison RS. Integrating Palliative Care with Chronic Liver Disease Care. J Palliat Care 2011;27:20-7. [DOI: 10.1177/082585971102700105] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
15 Terán A, Fábrega E, Pons-Romero F. [Pruritus associated with cholestasis]. Gastroenterol Hepatol 2010;33:313-22. [PMID: 19836105 DOI: 10.1016/j.gastrohep.2009.07.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Glasova H, Beuers U. Extrahepatic manifestations of cholestasis. Journal of Gastroenterology and Hepatology 2002;17:938-48. [DOI: 10.1046/j.1440-1746.2002.02717.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
17 Bergasa N, Liau S, Homel P, Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis: Met-enkephalin in PBC livers. Liver 2002;22:107-13. [DOI: 10.1034/j.1600-0676.2002.01458.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
18 Kremer AE, Oude Elferink RP, Beuers U. Cholestatic pruritus: new insights into pathophysiology and current treatment. Hautarzt. 2012;63:532-538. [PMID: 22733242 DOI: 10.1007/s00105-011-2321-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
19 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009;50:291-308. [PMID: 19554543 DOI: 10.1002/hep.22906] [Cited by in Crossref: 850] [Cited by in F6Publishing: 705] [Article Influence: 65.4] [Reference Citation Analysis]
20 Bergasa NV, Vergalla J, Swain MG, Jones EA. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 1996;16:298-302. [DOI: 10.1111/j.1600-0676.1996.tb00749.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
21 Tennyson H, Levine N. NEUROTROPIC AND PSYCHOTROPIC DRUGS IN DERMATOLOGY. Dermatologic Clinics 2001;19:179-97. [DOI: 10.1016/s0733-8635(05)70239-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
22 Rinaldi G. The Itch-Scratch Cycle: A Review of the Mechanisms. Dermatol Pract Concept 2019;9:90-7. [PMID: 31106010 DOI: 10.5826/dpc.0902a03] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
23 Bergasa NV, Mehlman J, Bir K. Aerobic exercise: a potential therapeutic intervention for patients with liver disease. Medical Hypotheses 2004;62:935-41. [DOI: 10.1016/j.mehy.2003.12.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
24 Moezi L, Shafaroodi H, Sarkar S, Emami-Razavi SH, Sanatkar M, Mirazi N, Dehpour AR. Involvement of nitrergic and opioidergic systems in the hypothermia induced by cholestasis in rats. Pathophysiology 2006;13:227-32. [PMID: 16963238 DOI: 10.1016/j.pathophys.2006.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
25 Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC, Park Y, Hoofnagle JH, Jones EA. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102:544-9. [PMID: 1732125 DOI: 10.1016/0016-5085(92)90102-5] [Cited by in Crossref: 196] [Cited by in F6Publishing: 167] [Article Influence: 6.5] [Reference Citation Analysis]
26 McRae CA, Prince MI, Hudson M, Day CP, James OF, Jones DE. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003;125:591-6. [PMID: 12891561 DOI: 10.1016/s0016-5085(03)00879-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
27 Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006;26:943-948. [PMID: 16953834 DOI: 10.1111/j.1478-3231.2006.01326.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 77] [Article Influence: 6.8] [Reference Citation Analysis]
28 Lang ME, Jourd'heuil D, Meddings JB, Swain MG. Increased opioid binding to peripheral white blood cells in a rat model of acute cholestasis. Gastroenterology 1995;108:1479-86. [DOI: 10.1016/0016-5085(95)90697-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
29 Dehpour AR, Seyyedi A, Rastegar H, Namiranian K, Moezi L, Sadeghipour H, Dehghani M, Jorjani M, Roushanzamir F, Ahmadiani A. The nonadrenergic noncholinergic relaxation of anococcygeus muscles of bile duct-ligated rats. Eur J Pharmacol 2002;445:31-6. [PMID: 12065191 DOI: 10.1016/s0014-2999(02)01659-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Terra SG, Tsunoda SM. Opioid antagonists in the treatment of pruritus from cholestatic liver disease. Ann Pharmacother 1998;32:1228-30. [PMID: 9825091 DOI: 10.1345/aph.18115] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
31 Kim D, Shin B, Song I, Han S, Gwak M, Kim G, Kim J, Choi G, Ko J. Relationship Between Intraoperative Bispectral Index and Consciousness Recovery in Patients With Hepatic Encephalopathy Undergoing Liver Transplant: A Retrospective Analysis. Transplantation Proceedings 2019;51:798-804. [DOI: 10.1016/j.transproceed.2018.10.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
32 Kam PCA, Tan KH. Pruritus-itching for a cause and relief? Anaesthesia 1996;51:1133-8. [DOI: 10.1111/j.1365-2044.1996.tb15050.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
33 Chakass D, Philippe D, Erdual E, Dharancy S, Malapel M, Dubuquoy C, Thuru X, Gay J, Gaveriaux-Ruff C, Dubus P, Mathurin P, Kieffer BL, Desreumaux P, Chamaillard M. micro-Opioid receptor activation prevents acute hepatic inflammation and cell death. Gut 2007;56:974-81. [PMID: 17299060 DOI: 10.1136/gut.2006.105122] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
34 Sanjel B, Shim WS. Recent advances in understanding the molecular mechanisms of cholestatic pruritus: A review. Biochim Biophys Acta Mol Basis Dis 2020;1866:165958. [PMID: 32896605 DOI: 10.1016/j.bbadis.2020.165958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Angulo P, Lindor KD. PRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS. Clinics in Liver Disease 1999;3:529-70. [DOI: 10.1016/s1089-3261(05)70084-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
36 Kumar G, Sethi N, Pant D, Sood J, Singh A, Pandey S, Dutta A. Comparison of bispectral index targeted end-tidal concentration of desflurane during three phases of orthotopic liver transplantation. Indian J Anaesth 2019;63:225-30. [PMID: 30988538 DOI: 10.4103/ija.IJA_693_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Elias E, Burra P. Primary biliary cirrhosis: symptomatic treatment. J Gastroenterol Hepatol 1991;6:570-3. [PMID: 1782372 DOI: 10.1111/j.1440-1746.1991.tb00912.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
38 Tohda C, Yamaguchi T, Kuraishi Y. Intracisternal Injection of Opioids Induces Itch-Associated Response through μ-Opioid Receptors in Mice. Japanese Journal of Pharmacology 1997;74:77-82. [DOI: 10.1016/s0021-5198(19)31429-5] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
39 Thomas DA, Hammond DL. Microinjection of morphine into the rat medullary dorsal horn produces a dose-dependent increase in facial scratching. Brain Research 1995;695:267-70. [DOI: 10.1016/0006-8993(95)00871-m] [Cited by in Crossref: 40] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
40 Zellos A, Roy A, Schwarz KB. Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children. J Pediatr Gastroenterol Nutr 2010;51:787-9. [PMID: 20948447 DOI: 10.1097/MPG.0b013e3181eb5ac0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
41 Bergasa NV. Hypothesis: Taste Disorders in Patients With Liver Disease May Be Mediated in the Brain: Potential Mechanisms for a Central Phenomenon. American Journal of Gastroenterology 1998;93:1209-10. [DOI: 10.1111/j.1572-0241.1998.00396.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
42 Düll MM, Kremer AE. Management of Chronic Hepatic Itch. Dermatologic Clinics 2018;36:293-300. [DOI: 10.1016/j.det.2018.02.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
43 Mitchison HC, Bassendine MF. Rolling review: autoimmune liver disease. Alimentary Pharmacology & Therapeutics 1993;7:93-109. [DOI: 10.1111/j.1365-2036.1993.tb00075.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:28:2:147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
45 Langedijk JAGM, Beuers UH, Oude Elferink RPJ. Cholestasis-Associated Pruritus and Its Pruritogens. Front Med (Lausanne) 2021;8:639674. [PMID: 33791327 DOI: 10.3389/fmed.2021.639674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Rayatzadeh H, Nouri M, Ghasemi M, Kebriaeezadeh A, Mehr SE, Dehpour AR. Effect of metal chelating agents on pentylenetetrazole-induced seizure threshold in cholestatic mice. Seizure 2009;18:51-6. [PMID: 18703360 DOI: 10.1016/j.seizure.2008.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
47 Hägermark O, Wahlgren CF. Treatment of itch. Semin Dermatol 1995;14:320-5. [PMID: 8679439 DOI: 10.1016/s1085-5629(05)80055-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
48 Nicoll J, Axiotis CA, Bergasa NV. The delta opioid receptor 1 is expressed by proliferating bile ductules in rats with cholestasis: implications for the study of liver regeneration and malignant transformation of biliary epithelium. Med Hypotheses. 2005;65:1099-1105. [PMID: 16125331 DOI: 10.1016/j.mehy.2005.06.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
49 Mcloughlin L, Medbak S, Grossman AB. Circulating Opioids in Man. In: Herz A, Akil H, Simon EJ, editors. Opioids II. Berlin: Springer Berlin Heidelberg; 1993. pp. 673-96. [DOI: 10.1007/978-3-642-77540-6_28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
50 Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993;53:1253-7. [PMID: 8412484 DOI: 10.1016/0024-3205(93)90569-o] [Cited by in Crossref: 44] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
51 Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones E. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. Journal of the American Academy of Dermatology 1999;41:431-4. [DOI: 10.1016/s0190-9622(99)70117-9] [Cited by in Crossref: 117] [Cited by in F6Publishing: 12] [Article Influence: 5.1] [Reference Citation Analysis]
52 Khanna A, Jones DE. Novel strategies and therapeutic options for the management of primary biliary cholangitis. Therap Adv Gastroenterol 2017;10:791-803. [PMID: 29051789 DOI: 10.1177/1756283X17728669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
53 Agrawal S, O'Connor R, Aoun E, Babich M. Intense pruritus in Epstein-Barr virus (EBV) hepatitis treated with naloxone drip. BMJ Case Rep 2015;2015:bcr2014207037. [PMID: 25628319 DOI: 10.1136/bcr-2014-207037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Bateson MC. New directions in primary biliary cirrhosis. BMJ 1990;301:1290-1. [PMID: 2271850 DOI: 10.1136/bmj.301.6764.1290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
55 Carbone M, Neuberger J. Liver transplantation in PBC and PSC: Indications and disease recurrence. Clinics and Research in Hepatology and Gastroenterology 2011;35:446-54. [DOI: 10.1016/j.clinre.2011.02.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
56 Wahlgren CF. Itch and atopic dermatitis: an overview. J Dermatol 1999;26:770-9. [PMID: 10635621 DOI: 10.1111/j.1346-8138.1999.tb02090.x] [Cited by in Crossref: 155] [Cited by in F6Publishing: 123] [Article Influence: 7.0] [Reference Citation Analysis]
57 Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis. 2004;8:133-149, vii. [PMID: 15062197 DOI: 10.1016/s1089-3261(03)00133-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
58 Schwörer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995;61:33-7. [DOI: 10.1016/0304-3959(94)00145-5] [Cited by in Crossref: 108] [Cited by in F6Publishing: 89] [Article Influence: 4.0] [Reference Citation Analysis]
59 Ostadhadi S, Haddadi N, Foroutan A, Azimi E, Elmariah S, Dehpour A. Development of resistance to serotonin-induced itch in bile duct ligated mice. Clin Exp Pharmacol Physiol 2017;44:680-5. [DOI: 10.1111/1440-1681.12752] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
60 Kang JG, Ko JS, Kim GS, Gwak MS, Kim YR, Lee SK. The relationship between inhalational anesthetic requirements and the severity of liver disease in liver transplant recipients according to three phases of liver transplantation. Transplant Proc. 2010;42:854-857. [PMID: 20430189 DOI: 10.1016/j.transproceed.2010.02.057] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
61 Muddu AK, Guha IN, Elsharkawy AM, Mann DA. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int J Biochem Cell Biol 2007;39:695-714. [PMID: 17110155 DOI: 10.1016/j.biocel.2006.10.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
62 Hosseini N, Alaei H, Zarrindast MR, Nasehi M, Radahmadi M. Cholestasis progression effects on long-term memory in bile duct ligation rats. Adv Biomed Res 2014;3:215. [PMID: 25371872 DOI: 10.4103/2277-9175.143263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
63 Bergasa NV, Zhou J, Ravi J, Shi Q. The opioid peptide analog d-Ala2-Met-enkephalinamide decreases bile flow by a central mechanism☆. Peptides 1999;20:979-86. [DOI: 10.1016/s0196-9781(99)00091-1] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
64 Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31:1005-1013. [PMID: 10733559 DOI: 10.1053/he.2000.5984] [Cited by in Crossref: 290] [Cited by in F6Publishing: 249] [Article Influence: 13.2] [Reference Citation Analysis]
65 Hasanein P, Javanmardi K. A potent and selective inhibitor of endocannabinoid uptake, UCM707, potentiates antinociception induced by cholestasis. Fundam Clin Pharmacol 2008;22:517-22. [PMID: 18844724 DOI: 10.1111/j.1472-8206.2008.00626.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
66 Homayoun H, Sayyah M, Dehpour AR. The additive effect of opioids and nitric oxide in increasing pentylenetetrazole-induced seizure threshold in cholestatic mice. J Gastroenterol Hepatol 2002;17:96-101. [DOI: 10.1046/j.1440-1746.2002.02658.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
67 Donovan KL, Janicki PK, Striepe VI, Stoica C, Franks WT, Pinson CW. DECREASED PATIENT ANALGESIC REQUIREMENTS AFTER LIVER TRANSPLANTATION AND ASSOCIATED NEUROPEPTIDE LEVELS: . Transplantation 1997;63:1423-9. [DOI: 10.1097/00007890-199705270-00010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
68 Turner IB, Rawlins MD, Wood P, James OF. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther. 1994;8:337-342. [PMID: 7918930 DOI: 10.1111/j.1365-2036.1994.tb00297.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
69 Gillespie DA, Vickers CR. Pruritus and cholestasis: Therapeutic options. J Gastroenterol Hepatol 1993;8:168-73. [DOI: 10.1111/j.1440-1746.1993.tb01510.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
70 Shawcross DL, Jalan R. Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. Gastroenterology 2001;121:743-4. [PMID: 11547785 DOI: 10.1053/gast.2001.27714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
71 Tandon P, Rowe BH, Vandermeer B, Bain VG. The Efficacy and Safety of Bile Acid Binding Agents, Opioid Antagonists, or Rifampin in the Treatment of Cholestasis-Associated Pruritus. Am J Gastroenterology 2007;102:1528-36. [DOI: 10.1111/j.1572-0241.2007.01200.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 76] [Article Influence: 7.5] [Reference Citation Analysis]
72 Janas RM, Socha J, Warnawin K, Rujner J. Further studies on aminopeptidase-M in blood in children with cholestatic liver diseases and viral hepatitis. Dig Dis Sci 1999;44:170-6. [PMID: 9952239 DOI: 10.1023/a:1026626822298] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
73 Hasanein P. Two histamine H 2 receptor antagonists, zolantidine and cimetidine, modulate nociception in cholestatic rats. J Psychopharmacol 2011;25:281-8. [DOI: 10.1177/0269881109106912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
74 Bertolotti M, Ferrari A, Vitale G, Stefani M, Trenti T, Loria P, Carubbi F, Carulli N, Sternieri E. Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J Hepatol 1997;27:505-11. [PMID: 9314128 DOI: 10.1016/s0168-8278(97)80355-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
75 Pauli-magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuhlmann U, Mettang T. Naltrexone Does Not Relieve Uremic Pruritus: Results of a Randomized, Double-Blind, Placebo-Controlled Crossover Study. JASN 2000;11:514-9. [DOI: 10.1681/asn.v113514] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
76 Mombeini T, Roushanzamir F, Jorjani M, Pourpak Z, Gaskari SA, Mehr SE, Dehpour AR. Alteration in specific opioid-receptor labeling on peripheral blood leukocytes of bile duct-ligated rat. Pathophysiology 2006;13:111-7. [DOI: 10.1016/j.pathophys.2006.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
77 Ong JP, Mullen KD. Hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2001;13:325-334. [PMID: 11338058 DOI: 10.1097/00042737-200104000-00005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
78 Gingold AR, Bergasa NV. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sciences 2003;73:2741-7. [DOI: 10.1016/s0024-3205(03)00668-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
79 Jiang Q, Jiang G, Welty TE, Zheng M. Naloxone in the management of hepatic encephalopathy. J Clin Pharm Ther. 2010;35:333-341. [PMID: 20831534 DOI: 10.1111/j.1365-2710.2009.01120.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
80 Greco PJ, Ende J. Pruritus: A practical approach. J Gen Intern Med 1992;7:340-9. [DOI: 10.1007/bf02598094] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
81 Borgeat A, Wilder-smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993;104:244-7. [DOI: 10.1016/0016-5085(93)90858-a] [Cited by in Crossref: 46] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
82 Reza Zarrindast M, Eslimi Esfahani D, Oryan S, Nasehi M, Torabi Nami M. Effects of dopamine receptor agonist and antagonists on cholestasis-induced anxiolytic-like behaviors in rats. European Journal of Pharmacology 2013;702:25-31. [DOI: 10.1016/j.ejphar.2013.01.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
83 Mccormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, Mcintyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. Journal of Hepatology 1994;21:496-9. [DOI: 10.1016/s0168-8278(94)80092-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
84 Terzioğlu B, Aypak C, Yananlı HR, Küçükibrahimoğlu E, Yurdaydın C, Gören MZ. 5-hydroxytryptamine release in the anterior hypothalamic and the hippocampal areas of cholestatic rats. Life Sciences 2006;78:1078-83. [DOI: 10.1016/j.lfs.2005.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
85 Reid LD, Hubbell CL. Opioids Modulate Rats’ Propensities to Take Alcoholic Beverages. In: Naranjo CA, Sellers EM, editors. Novel Pharmacological Interventions for Alcoholism. New York: Springer; 1992. pp. 121-34. [DOI: 10.1007/978-1-4612-2878-3_10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
86 Düll MM, Kremer AE. Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease. Curr Hepatology Rep 2020;19:86-95. [DOI: 10.1007/s11901-020-00517-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Swain MG, Heyes MP, Vergalla J, Jones E. Methionine enkephalin accumulates in plasma but not in brain or cerebrospinal fluid of rats with acute toxic hepatitis. Neuroscience Letters 1992;141:243-6. [DOI: 10.1016/0304-3940(92)90904-l] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
88 Kremer AE, Feramisco J, Reeh PW, Beuers U, Oude Elferink RP. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2014;1842:869-92. [DOI: 10.1016/j.bbadis.2014.02.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
89 Bergasa NV, Jones E. The pruritus of cholestasis: Potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995;108:1582-8. [DOI: 10.1016/0016-5085(95)90709-2] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 2.9] [Reference Citation Analysis]
90 Marzioni M, Saccomanno S, Candelaresi C, Rychlicki C, Agostinelli L, Trozzi L, De Minicis S, Benedetti A. Clinical implications of novel aspects of biliary pathophysiology. Dig Liver Dis 2010;42:238-44. [PMID: 20167547 DOI: 10.1016/j.dld.2010.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
91 Cao T, Tey HL, Yosipovitch G. Chronic Pruritus in the Geriatric Population. Dermatol Clin. 2018;36:199-211. [PMID: 29929593 DOI: 10.1016/j.det.2018.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
92 Gossard AA, Talwalkar JA. Cholestatic liver disease. Med Clin North Am 2014;98:73-85. [PMID: 24266915 DOI: 10.1016/j.mcna.2013.09.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
93 Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones E. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992;103:630-5. [DOI: 10.1016/0016-5085(92)90857-u] [Cited by in Crossref: 127] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
94 Hasanin AS, Mahmoud FM, Yassen KA. Entropy-guided end-tidal desflurane concentration during living donor liver transplantation. Saudi J Anaesth 2013;7:399-403. [PMID: 24348290 DOI: 10.4103/1658-354X.121048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Bergasa NV. Update on the Treatment of the Pruritus of Cholestasis. Clinics in Liver Disease 2008;12:219-34. [DOI: 10.1016/j.cld.2007.11.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
96 Wahler JB, Swain MG, Carson R, Bergasa NV, Jones EA. Blood-brain barrier permeability is markedly decreased in cholestasis in the rat. Hepatology 1993;17:1103-8. [DOI: 10.1002/hep.1840170625] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
97 Zylicz Z, Krajnik M. Codeine for pruritus in primary billiary cirrhosis. The Lancet 1999;353:813. [DOI: 10.1016/s0140-6736(99)00259-7] [Cited by in Crossref: 14] [Article Influence: 0.6] [Reference Citation Analysis]
98 Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994;107:1844-7. [PMID: 7958700 DOI: 10.1016/0016-5085(94)90830-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
99 Ebrahimkhani MR, Kiani S, Oakley F, Kendall T, Shariftabrizi A, Tavangar SM, Moezi L, Payabvash S, Karoon A, Hoseininik H, Mann DA, Moore KP, Mani AR, Dehpour AR. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut 2006;55:1606-16. [PMID: 16543289 DOI: 10.1136/gut.2005.076778] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 3.4] [Reference Citation Analysis]
100 Hasanein P. Histamine H3 receptor modulates nociception in a rat model of cholestasis. Pharmacology Biochemistry and Behavior 2010;96:312-6. [DOI: 10.1016/j.pbb.2010.05.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
101 Bergasa NV, Jones EA. THE PRURITUS OF CHOLESTASIS. Clinics in Liver Disease 1998;2:391-405. [DOI: 10.1016/s1089-3261(05)70014-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
102 O'Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, Williams R. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther 2005;21:1041-5. [PMID: 15813840 DOI: 10.1111/j.1365-2036.2005.02430.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
103 Bassari R, Koea JB. Jaundice associated pruritis: A review of pathophysiology and treatment. World J Gastroenterol 2015; 21(5): 1404-1413 [PMID: 25663760 DOI: 10.3748/wjg.v21.i5.1404] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
104 Sadeghipour H, Dehghani M, Dehpour AR. Role of opioid and nitric oxide systems in the nonadrenergic noncholinergic-mediated relaxation of corpus cavernosum in bile duct-ligated rats. European Journal of Pharmacology 2003;460:201-7. [DOI: 10.1016/s0014-2999(02)02946-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Rees W. Opioid needs of terminal care patients: Variations with age and primary site. Clinical Oncology 1990;2:79-83. [DOI: 10.1016/s0936-6555(05)80792-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
106 Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology. 1990;11:884-887. [PMID: 2161397 DOI: 10.1002/hep.1840110526] [Cited by in Crossref: 141] [Cited by in F6Publishing: 116] [Article Influence: 4.4] [Reference Citation Analysis]
107 Swain MG, Patchev V, Vergalla J, Chrousos G, Jones EA. Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis. J Clin Invest 1993;91:1903-8. [PMID: 8387536 DOI: 10.1172/JCI116408] [Cited by in Crossref: 69] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
108 Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology. 1999;29:1003-1006. [PMID: 10094938 DOI: 10.1002/hep.510290450] [Cited by in Crossref: 117] [Cited by in F6Publishing: 91] [Article Influence: 5.1] [Reference Citation Analysis]
109 Jones EA, Bergasa NV. Why do cholestatic patients itch? Gut 1996;38:644-5. [PMID: 8707105 DOI: 10.1136/gut.38.5.644] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
110 Marzioni M, Alpini G, Saccomanno S, de Minicis S, Glaser S, Francis H, Trozzi L, Venter J, Orlando F, Fava G, Candelaresi C, Macarri G, Benedetti A. Endogenous Opioids Modulate the Growth of the Biliary Tree in the Course of Cholestasis. Gastroenterology 2006;130:1831-47. [DOI: 10.1053/j.gastro.2006.02.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 77] [Article Influence: 2.0] [Reference Citation Analysis]
111 Mitchell SA, Chapman RWG. Review article: the management of primary sclerosing cholangitis. Aliment Pharmacol Ther 1997;11:33-43. [DOI: 10.1046/j.1365-2036.1997.91263000.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
112 Dehpour AR, Sadeghipour HR, Nowroozi A, Akbarloo N. The effect of the serotonergic system on opioid withdrawal-like syndrome in a mouse model of cholestasis. Hum Psychopharmacol 2000;15:423-8. [PMID: 12404304 DOI: 10.1002/1099-1077(200008)15:6<423::AID-HUP214>3.0.CO;2-V] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
113 Sanchez W, Talwalkar JA. Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am 2006;35:201-19. [PMID: 16530121 DOI: 10.1016/j.gtc.2005.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
114 Cies JJ, Giamalis JN. Treatment of cholestatic pruritus in children. American Journal of Health-System Pharmacy 2007;64:1157-62. [DOI: 10.2146/ajhp060453] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
115 Davis M. Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin Pharmacokinet 2007;46:825-50. [PMID: 17854233 DOI: 10.2165/00003088-200746100-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
116 Dehpour AR, Samini M, Rastegar H, Ardeshiri AJ, Roushanzamir F, Jorjani M, Ahmadiani A. Effect of NMDA receptor antagonist on naloxone-precipitated withdrawal signs in cholestatic mice. Hum Psychopharmacol Clin Exp 2000;15:213-8. [DOI: 10.1002/(sici)1099-1077(200004)15:3<213::aid-hup159>3.0.co;2-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
117 Bergasa NV. Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am. 2006;35:113-123. [PMID: 16530114 DOI: 10.1016/j.gtc.2005.12.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
118 Swain MG, Vergalla J, Jones EA. Plasma endopeptidase 24.11 (enkephalinase) activity is markedly increased in cholestatic liver disease. Hepatology 1993;18:556-8. [DOI: 10.1002/hep.1840180312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
119 Bergasa NV. The pruritus of cholestasis. Semin Dermatol 1995;14:302-12. [PMID: 8679436 DOI: 10.1016/s1085-5629(05)80052-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
120 Khanna A, Leighton J, Lee Wong L, Jones DE. Symptoms of PBC – Pathophysiology and management. Best Practice & Research Clinical Gastroenterology 2018;34-35:41-7. [DOI: 10.1016/j.bpg.2018.06.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
121 Krok KL, Munoz SJ. Management of autoimmune and cholestatic liver disorders. Clin Liver Dis 2009;13:295-316. [PMID: 19442920 DOI: 10.1016/j.cld.2009.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
122 Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000;118:431-2. [PMID: 10648471 DOI: 10.1016/s0016-5085(00)70225-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
123 Hasanein P. The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis. Neuroscience Letters 2009;462:230-4. [DOI: 10.1016/j.neulet.2009.07.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
124 Rahimi N, Hassanipour M, Allahabadi NS, Sabbaghziarani F, Yazdanparast M, Dehpour A. Cirrhosis induced by bile duct ligation alleviates acetic acid intestinal damages in rats: Involvements of nitrergic and opioidergic systems. Pharmacological Reports 2018;70:426-33. [DOI: 10.1016/j.pharep.2017.11.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
125 Umeuchi H, Kawashima Y, Aoki CA, Kurokawa T, Nakao K, Itoh M, Kikuchi K, Kato T, Okano K, Gershwin ME, Miyakawa H. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel κ-opioid receptor agonist nalfurafine hydrochloride. European Journal of Pharmacology 2005;518:133-9. [DOI: 10.1016/j.ejphar.2005.06.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
126 Nahavandi A, Mani AR, Homayounfar H, Akbari MR, Dehpour AR. The role of the interaction between endogenous opioids and nitric oxide in the pathophysiology of ethanol-induced gastric damage in cholestatic rats. Fundam Clin Pharmacol. 2001;15:181-187. [PMID: 11468029 DOI: 10.1046/j.1472-8206.2001.00028.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
127 Hasanein P, Shahidi S, Komaki A, Mirazi N. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis. Eur J Pharmacol 2008;591:132-5. [PMID: 18593578 DOI: 10.1016/j.ejphar.2008.06.061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
128 Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394-419. [PMID: 30070375 DOI: 10.1002/hep.30145] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 21.5] [Reference Citation Analysis]
129 Bigliardi PL, Dancik Y, Neumann C, Bigliardi‐qi M. Opioids and skin homeostasis, regeneration and ageing – What's the evidence? Exp Dermatol 2016;25:586-91. [DOI: 10.1111/exd.13021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
130 Greaves MW. New Pathophysiological and Clinical Insights into Pruritus. The Journal of Dermatology 1993;20:735-40. [DOI: 10.1111/j.1346-8138.1993.tb01376.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
131 Mettang T. Chronic Kidney Disease-Associated Pruritus. In: Misery L, Ständer S, editors. Pruritus. London: Springer; 2010. pp. 166-75. [DOI: 10.1007/978-1-84882-322-8_27] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
132 Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-22. [PMID: 12445410 DOI: 10.1016/s0168-8278(02)00318-5] [Cited by in Crossref: 113] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
133 Ebrahimi F, Tavakoli S, Hajrasouliha AR, Shafaroodi H, Sadeghipour H, Riazi K, Borhani AA, Houshmand G, Ahmadi SH, Dehpour AR. Contribution of endogenous opioids and nitric oxide to papillary muscle contractile impairment in cholestatic rats. Eur J Pharmacol 2005;523:93-100. [PMID: 16226248 DOI: 10.1016/j.ejphar.2005.08.057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
134 Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis. 2008;12:385-406; x. [PMID: 18456187 DOI: 10.1016/j.cld.2008.02.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
135 Schmelz M. [Opioid-induced pruritus. Mechanisms and treatment regimens]. Anaesthesist 2009;58:61-5. [PMID: 19132330 DOI: 10.1007/s00101-008-1478-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
136 Shafaroodi H, Ghasemi M, Dehpour AR. Elevation of pentylenetetrazole-induced seizure threshold in cholestatic mice: Interaction between opioid and cannabinoid systems. Journal of Gastroenterology and Hepatology 2008;23:e251-7. [DOI: 10.1111/j.1440-1746.2007.05101.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
137 Greaves MW. Pruritus. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. Oxford: Wiley-Blackwell; 2010. pp. 1-18. [DOI: 10.1002/9781444317633.ch21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
138 Aldersley MA, O'Grady JG. Hepatic disorders. Features and appropriate management. Drugs 1995;49:83-102. [PMID: 7705218 DOI: 10.2165/00003495-199549010-00007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
139 Wakefield AJ, Puleston JM, Montgomery SM, Anthony A, O'leary JJ, Murch SH. The concept of entero-colonic encephalopathy, autism and opioid receptor ligands: REVIEW: ENTERO-COLONIC ENCEPHALOPATHY, AUTISM AND OPIOIDS. Alimentary Pharmacology & Therapeutics 2002;16:663-74. [DOI: 10.1046/j.1365-2036.2002.01206.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
140 Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol. 2001;13:1393-1394. [PMID: 11692070 DOI: 10.1097/00042737-200111000-00022] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
141 Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol 2010;49:1-11. [PMID: 20465602 DOI: 10.1111/j.1365-4632.2009.04249.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
142 Poupon R, Poupon RE. Treatment of primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:615-628. [PMID: 10976018 DOI: 10.1053/bega.2000.0107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
143 Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones E. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. Journal of Hepatology 1992;15:220-4. [DOI: 10.1016/0168-8278(92)90040-v] [Cited by in Crossref: 91] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
144 Nasehi M, Piri M, Abbolhasani K, Zarrindast MR. Involvement of opioidergic and nitrergic systems in memory acquisition and exploratory behaviors in cholestatic mice. Behav Pharmacol 2013;24:180-94. [PMID: 23604167 DOI: 10.1097/FBP.0b013e3283618aab] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
145 Dehpour AR, Meysami F, Ebrahimi-daryani N, Akbarloo N. Inhibition by lithium of opioid withdrawal-like syndrome and physical dependency in a model of acute cholestasis in mice. Hum Psychopharmacol Clin Exp 1998;13:407-12. [DOI: 10.1002/(sici)1099-1077(199808)13:6<407::aid-hup11>3.0.co;2-c] [Cited by in Crossref: 11] [Article Influence: 0.5] [Reference Citation Analysis]
146 Bergasa NV. The pruritus of cholestasis. J Hepatol. 2005;43:1078-1088. [PMID: 16253381 DOI: 10.1016/j.jhep.2005.09.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
147 Ghafourifar P, Dehpour AR, Akbarloo N. Inhibition by L-NA, a nitric oxide synthase inhibitor, of naloxone-precpitated withdrawal signs in a mouse model of cholestasis. Life Sciences 1997;60:PL265-70. [DOI: 10.1016/s0024-3205(97)00115-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
148 Jones E. Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions. Journal of Hepatology 2002;37:863-5. [DOI: 10.1016/s0168-8278(02)00347-1] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
149 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
150 Jiang Q, Jiang G, Shi K, Cai H, Wang Y, Zheng M. Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Annals of Hepatology 2013;12:803-9. [DOI: 10.1016/s1665-2681(19)31323-7] [Cited by in Crossref: 24] [Article Influence: 2.7] [Reference Citation Analysis]
151 Choi YS, Billings J. Opioid Antagonists. Journal of Pain and Symptom Management 2002;24:71-90. [DOI: 10.1016/s0885-3924(02)00424-4] [Cited by in Crossref: 105] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
152 Eslimi D, Oryan S, Nasehi M, Zarrindast MR. Effects of opioidergic systems upon anxiolytic-like behaviors induced in cholestatic rats. European Journal of Pharmacology 2011;670:180-5. [DOI: 10.1016/j.ejphar.2011.08.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
153 Krishnan A, Koo J. Psyche, opioids, and itch: therapeutic consequences: Psyche, opioids, and itch. Dermatologic Therapy 2005;18:314-22. [DOI: 10.1111/j.1529-8019.2005.00038.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
154 Gossard AA. Care of the cholestatic patient. Clin Liver Dis 2013;17:331-44. [PMID: 23540506 DOI: 10.1016/j.cld.2012.11.005] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
155 Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:643-655. [PMID: 10976020 DOI: 10.1053/bega.2000.0109] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
156 Bergasa NV. Studying pruritus in the 21st century. Clinical Gastroenterology and Hepatology 2003;1:249-51. [DOI: 10.1016/s1542-3565(03)00140-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 Bergasa NV. An approach to the management of the pruritus of cholestasis. Clinics in Liver Disease 2004;8:55-66. [DOI: 10.1016/s1089-3261(03)00128-4] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
158 Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology. 1998;27:679-684. [PMID: 9500694 DOI: 10.1002/hep.510270307] [Cited by in Crossref: 127] [Cited by in F6Publishing: 102] [Article Influence: 5.3] [Reference Citation Analysis]
159 Ebrahimkhani MR, Elsharkawy AM, Mann DA. Wound healing and local neuroendocrine regulation in the injured liver. Expert Rev Mol Med. 2008;10:e11. [PMID: 18442446 DOI: 10.1017/S146239940800063X] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
160 Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. Journal of the American Academy of Dermatology 1999;41:533-9. [DOI: 10.1016/s0190-9622(99)80048-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
161 Georgala S, Schulpis KH, Papaconstantinou E, Stratigos J. Raised β-endorphin serum levels in children with atopic dermatitis and pruritus. Journal of Dermatological Science 1994;8:125-8. [DOI: 10.1016/0923-1811(94)90006-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
162 Hegade VS, Bolier R, Oude Elferink RP, Beuers U, Kendrick S, Jones DE. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Frontline Gastroenterol 2016;7:158-66. [PMID: 28839853 DOI: 10.1136/flgastro-2015-100618] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
163 Mitchell SA, Chapman RW. THE MANAGEMENT OF PRIMARY SCLEROSING CHOLANGITIS. Clinics in Liver Disease 1998;2:353-72. [DOI: 10.1016/s1089-3261(05)70012-x] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
164 Feramisco JD, Berger TG, Steinhoff M. Innovative management of pruritus. Dermatol Clin 2010;28:467-78. [PMID: 20510757 DOI: 10.1016/j.det.2010.03.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
165 Javadi-Paydar M, Ghiassy B, Ebadian S, Rahimi N, Norouzi A, Dehpour AR. Nitric oxide mediates the beneficial effect of chronic naltrexone on cholestasis-induced memory impairment in male rats. Behav Pharmacol 2013;24:195-206. [PMID: 23591123 DOI: 10.1097/FBP.0b013e3283618a8c] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
166 Hasanein P, Parviz M. Role of GABAA receptor in modulation of acute thermal pain using a rat model of cholestasis. Pharmacology Biochemistry and Behavior 2014;124:226-30. [DOI: 10.1016/j.pbb.2014.06.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
167 Hägermark Ö. Itch mediators. Seminars in Dermatology 1995;14:271-6. [DOI: 10.1016/s1085-5629(05)80047-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
168 Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012;16:331-46. [PMID: 22541702 DOI: 10.1016/j.cld.2012.03.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
169 Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008;3:1. [PMID: 18215315 DOI: 10.1186/1750-1172-3-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
170 Lonsdale-eccles A, Carmichael AJ. Treatment of Pruritus Associated with Systemic Disorders in the Elderly: A Review of the Role of New Therapies. Drugs & Aging 2003;20:197-208. [DOI: 10.2165/00002512-200320030-00004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
171 Bergasa NV. Treatment of the pruritus of cholestasis. Curr Treat Options Gastro 2004;7:501-8. [DOI: 10.1007/s11938-004-0009-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
172 Hasanein P, Parviz M, Keshavarz M, Javanmardi K, Allahtavakoli M, Ghaseminejad M. Modulation of cholestasis-induced antinociception in rats by two NMDA receptor antagonists: MK-801 and magnesium sulfate. Eur J Pharmacol 2007;554:123-7. [PMID: 17107671 DOI: 10.1016/j.ejphar.2006.10.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
173 Kuraishi Y, Yamaguchi T, Miyamoto T. Itch-scratch responses induced by opioids through central Mu opioid receptors in mice. J Biomed Sci 2000;7:248-52. [DOI: 10.1007/bf02255473] [Cited by in Crossref: 46] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
174 Sullivan JR, Watson A. Naltrexone: a case report of pruritus from an antipruritic. Australas J Dermatol 1997;38:196-8. [PMID: 9431714 DOI: 10.1111/j.1440-0960.1997.tb01696.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
175 Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol. 2011;35:89-97. [PMID: 21809485 DOI: 10.1016/j.clinre.2010.10.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
176 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
177 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
178 Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
179 Jones E, Zylicz Z. Treatment of Pruritus Caused by Cholestasis with Opioid Antagonists. Journal of Palliative Medicine 2005;8:1290-4. [DOI: 10.1089/jpm.2005.8.1290] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
180 Ghaffari K, Savadkuhi ST, Honar H, Riazi K, Shafaroodi H, Moezi L, Ebrahimkhani MR, Tahmasebi MS, Dehpour AR. Obstructive cholestasis alters intestinal transit in mice: role of opioid system. Life Sci. 2004;76:397-406. [PMID: 15530502 DOI: 10.1016/j.lfs.2004.09.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
181 Gaskari SA, Mani AR, Ejtemaei-Mehr S, Namiranian K, Homayoun H, Ahmadi H, Dehpour AR. Do endogenous opioids contribute to the bradycardia of rats with obstructive cholestasis? Fundam Clin Pharmacol 2002;16:273-9. [PMID: 12570015 DOI: 10.1046/j.1472-8206.2002.00089.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
182 Danno K, Nishiura K, Tanaka M. Increased met-enkephalin plasma levels in hemodialysis patients with or without pruritus. Journal of Dermatological Science 1995;10:238-40. [DOI: 10.1016/0923-1811(95)00451-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
183 Khandelwal M, Malet PF. Pruritus associated with cholestasis. A review of pathogenesis and management. Dig Dis Sci 1994;39:1-8. [PMID: 8281842 DOI: 10.1007/BF02090052] [Cited by in Crossref: 36] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
184 Mani AR, Rasool R, Montagnese S, Dehpour AR. Endogenous opioids and liver disease. Scandinavian Journal of Gastroenterology 2009;41:1-11. [DOI: 10.1080/00365520500287533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
185 Düll MM, Wolf K, Vetter M, Dietrich P, Neurath MF, Kremer AE. Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus. Front Med (Lausanne) 2021;8:641163. [PMID: 33937284 DOI: 10.3389/fmed.2021.641163] [Reference Citation Analysis]
186 Cunha PR, Delfini Filho O. Pruritus: still a challenge. An Bras Dermatol 2012;87:735-41. [PMID: 23044567 DOI: 10.1590/s0365-05962012000500011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
187 Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis. 2003;7:879-900. [PMID: 14594135 DOI: 10.1016/s1089-3261(03)00105-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
188 Thornton JR, Losowsky MS. Plasma leucine enkephalin is increased in liver disease. Gut 1989;30:1392-5. [PMID: 2583565 DOI: 10.1136/gut.30.10.1392] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.0] [Reference Citation Analysis]
189 Bergasa NV, Mohajer B, Maisonneuve IM, Ho A, Maidment NT, Olive F, Gunduz M, Kreek MJ. Basal total opioid peptide release in the striatum of rats with cholestasis from bile duct resection: a study by the use of in vivo microdialysis. Life Sci 1997;61:1169-75. [PMID: 9315507 DOI: 10.1016/s0024-3205(97)00658-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
190 Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63:680-688. [PMID: 20462660 DOI: 10.1016/j.jaad.2009.08.052] [Cited by in Crossref: 109] [Cited by in F6Publishing: 77] [Article Influence: 9.1] [Reference Citation Analysis]
191 Hajrasouliha AR, Tavakoli S, Jabehdar-Maralani P, Ebrahimi F, Shafaroodi H, Mirkhani SH, Amanpour S, Dehpour AR. Cholestatic liver disease modulates susceptibility to ischemia/reperfusion-induced arrhythmia, but not necrosis and hemodynamic instability: the role of endogenous opioid peptides. J Hepatol 2005;43:491-8. [PMID: 16023251 DOI: 10.1016/j.jhep.2005.02.043] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
192 Bergasa NV. Pruritus in chronic liver disease: mechanisms and treatment. Curr Gastroenterol Rep 2004;6:10-6. [PMID: 14720448 DOI: 10.1007/s11894-004-0020-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
193 Patel SP, Vasavda C, Ho B, Meixiong J, Dong X, Kwatra SG. Cholestatic pruritus: Emerging mechanisms and therapeutics. J Am Acad Dermatol 2019;81:1371-8. [PMID: 31009666 DOI: 10.1016/j.jaad.2019.04.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
194 Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther. 2003;17:857-870. [PMID: 12656688 DOI: 10.1046/j.1365-2036.2003.01458.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
195 Yurdaydin C, Karavelioglu D, Onaran O, Celik T, Yaşa MH, Uzunalimoglu O. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol 1998;29:796-801. [PMID: 9833918 DOI: 10.1016/s0168-8278(98)80261-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
196 Wakasa Y, Fujiwara A, Umeuchi H, Endoh T, Okano K, Tanaka T, Nagase H. Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sciences 2004;75:2947-57. [DOI: 10.1016/j.lfs.2004.05.033] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
197 Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol 2008;22:505-7. [PMID: 18478137 DOI: 10.1155/2008/969826] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
198 Demehri S, Samini M, Namiranian K, Rastegar H, Mehr SE, Homayoun H, Roushanzamir F, Jorjani M, Dehpour AR. Alpha2-adrenoceptor and NO mediate the opioid subsensitivity in isolated tissues of cholestatic animals. Autonom & Auta Pharm 2003;23:201-7. [DOI: 10.1046/j.1474-8673.2003.00297.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
199 Jiang PP, Guo YX, Yang XL, Xu J, Wang D. Effects of different remifentanil target concentrations on MACBAR of sevoflurane in patients with liver dysfunction under carbon dioxide pneumoperitoneum stimulus: A randomized controlled trial. J Clin Pharm Ther 2021;46:1776-83. [PMID: 34514614 DOI: 10.1111/jcpt.13524] [Reference Citation Analysis]